Evidence map›Paper›PMID 40597155›Full record

ArticleBMC biotechnology2025

Self-assembling T7 phage syringes with modular genomes for targeted delivery of penicillin against β-lactam-resistant Escherichia coli.

Hyunjin Shim

Abstract read
In one paragraph

Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hyunjin ShimDepartment of Biology, California State University, 5241 N Maple Ave, Fresno, CA, 93740, USA. shim@csufresno.edu.ORCID 0000-0002-7052-0971

Funding

Surveillance of drug-resistant bacteria in resource-limited settings: a focus on cost-effective long-read sequencing of eyedrop-associated P. aeruginosa and locally sourced metagenomic samplesR16AI184350 · NIAID · CALIFORNIA STATE UNIVERSITY FRESNO · PI Hyunjin Shim · 2024 to 2026
$525k
NIAID NIH HHS R16 AI184350NIH HHS 1R16AI184350-01
6 · The paper itself

Abstract

Bacteriophages are promising alternative antimicrobial agents due to their high specificity for host bacteria and minimal immunogenicity in humans. However, their therapeutic application is limited by their nature as biological entities, with potential evolutionary consequences. In this study, we address these challenges by repurposing only the structural components of bacteriophages as vesicles to deliver antibiotics directly into the cytoplasm of bacterial hosts. This approach is based on two key hypotheses: first, antibiotics such as β-lactams remain effective against resistant bacteria if injected directly into the cytoplasm, bypassing resistance mechanisms; second, phage structures can be synthesized and self-assembled in vitro using modular genomes and cell-free protein expression to carry small molecules as cargo. To test these hypotheses, we utilized T7 phages and penicillin-resistant Escherichia coli as a model system. First, we designed the T7 phage genome into a modular format containing only the genes encoding structural components and synthesized the gene fragments via de novo gene synthesis. These phage structures were then rebooted in vitro using cell-free protein expression in the presence of penicillin G, allowing the antibiotics to be incorporated as cargo during the self-assembly process. Finally, we tested the antimicrobial activity of these antibiotic-loaded phage syringes against penicillin-resistant E. coli. The results demonstrate that phage syringes effectively reduce the host population compared to negative controls, including free penicillin and water. This study highlights the potential of using phage structures as antibiotic delivery vehicles, offering a novel strategy to overcome both the limitations of small-molecule antibiotics and phage therapy.

Indexed as

Anti-Bacterial AgentsBacteriophage T7Drug Delivery SystemsEscherichia coliPenicillinsbeta-Lactam ResistanceGenome, ViralAnti-Bacterial AgentsPenicillinsAntibioticsAntimicrobial resistancePenicillinPhage rebootPhage therapyβ lactam

Identifiers

PMID40597155
PMCPMC12220360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.